Using LGR5-targetedantibody–drug conjugates, Gong and coworkers showed that targetingLGR5+ cells led to tumor eradication and prevention of disease recurrence ina xenograft model of colon cancer (Gong etal. 2016). Here, LGR5 is linked to colonic neoplasm.